Trials / Recruiting
RecruitingNCT06605222
A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors
A Phase I/II, Open Label, Multicenter Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-7787 in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 201 (estimated)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-7787 injection monotherapy for patients with advanced solid tumors. To explore the reasonable dosage of SHR-7787 injection monotherapy for patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-7787 injection | Firstly Dose Escalation and Dose Expansion of SHR-7787 injection monotherapy should be conducted. |
Timeline
- Start date
- 2024-10-04
- Primary completion
- 2026-07-31
- Completion
- 2026-11-30
- First posted
- 2024-09-20
- Last updated
- 2024-10-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06605222. Inclusion in this directory is not an endorsement.